FDA clears AngioDynamics' device to reduce blood clots

08/21/2013 | Post-Star (Glens Falls, N.Y.), The · RTT News

The FDA has cleared AngioDynamics to market its BioFlo Port with Endexo system. The device, which is implanted below the skin, is used to minimize the risk of blood clots among patients in need of prolonged or frequent access to the cardiovascular system for chemotherapy and other treatments.

View Full Article in:

Post-Star (Glens Falls, N.Y.), The · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ